Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing Phase 3 trial of pacritinib, the Company's JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI® (pixantrone).

This is a partial clinical hold of only part of the clinical work requested under the investigational new drug ("IND") application. Under a partial clinical hold, although a specific protocol or part of a protocol is not allowed to proceed, other parts of such protocol or other protocols are allowed to proceed under the IND. With this partial clinical hold, the Company may not enter new patients onto any of the ongoing tosedostat protocols until agreement is reached with the FDA.

After a study has been placed on partial clinical hold, the sponsor provides additional information and discusses the adverse event with the FDA to understand whether or not it was associated with the drug or due to another cause. The Company has begun work to comply with the FDA request and expects to be able to submit these data to the FDA in the coming weeks. For additional information, please refer to the Current Report on Form 8-K filed by the Company on June 24, 2013.

Recent Tosedostat Publication
In March 2013, Lancet Oncology published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). The trial showed that once-daily oral tosedostat resulted in a disease contro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 ... report is available in its catalogue: ... 2014-2024 http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... – discover technological and commercial prospects What ... delivery market? Visiongain,s brand new report shows ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
(Date:8/28/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today updates the timeline for the GMP ... The Company is scheduled to submit ... Food & Drug Administration,s (CFDA) review in the ...
Breaking Medicine Technology:Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... The High Court of Germany ( Bundesgerichtshof ) handed ... in its dispute with the Finnish company Medix Biochemica. The ... associated with Medix,s ActimPROM test is null and void due ... to pay AmniSure® an undisclosed amount to be determined by ...
... -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX ... products and services in the People,s Republic of China, ... results for the three and nine-month periods ended December ... market closes. Management will host a conference call at ...
Cached Medicine Technology:German High Court Rules in Favor of AmniSure® as New European Guidelines Published 2Chindex International to Report Financial Results for the Three and Nine-Month Periods Ended December 31, 2010 2
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
(Date:8/29/2014)... 2014 The 8th Annual Paint Columbus Pink® ... a Cause, Pink Pooch Contest, Light of Life Ceremony, Power ... Pink Bow Campaign – all in support of cancer awareness. ... this year…. Paint Columbus Pink Foam and Obstacle Challenge on ... 727 54th Street, Columbus, Georgia 31904. It will be the ...
(Date:8/29/2014)... 29, 2014 After having a double ... had to have breast reconstruction. She found that the ... she decided that there needed to be a solution. ... a woman or man who needs or wants breast ... promotes confidence and peace of mind. Producible in design ...
(Date:8/29/2014)... 2014 University of Western States (UWS), ... announced that Daniel Redwood, DC, director of the human ... the Year,” by the Missouri State Chiropractors Association (MSCA) ... , Patrick Montgomery, DC, president of the MSCA, cited ... Missouri House Task Force for Medicaid Reform, in bringing ...
Breaking Medicine News(10 mins):Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2
... June 03, 2010 The John Theurer Cancer Center ... physicians and researchers will present 16 abstracts on treatment ... during the Annual Meeting of American Society of Clinical ... "At the John Theurer Cancer Center, we,re ...
... Americans now have choices ... treatment in the USA, Medical Tourism is the answer. , ... Carlsbad, CA (PRWEB) June 2, 2010 – Website promotes the healthcare options ... USA. , , ,Global Medical Connect is a one stop medical tourism shop to take care ...
... , THURSDAY, June 3 (HealthDay News) -- Fatal medication ... of the inexperience of new medical residents, a new ... July, and those first weeks may be a dangerous ... the University of California, San Diego. , The ...
... say it,s not always that simple, , THURSDAY, June 3 ... in many a parent. But having to incorporate information ... make an already sensitive subject even more complicated. , Yet ... As assisted reproduction technology, in which someone other than the ...
... ... Lake Host Malaria Awareness Soccer Clinic this Thursday for Local Youth as part of White ... ... the United Nations Foundation ’s Nothing But Nets campaign are teaming up to raise ...
... ... research study that provides detailed analyses on health plans’ coverage and management of ... ... Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on ...
Cached Medicine News:Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 2Health News:Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO 3Health News:Global Medical Connect Launches New Website for the Growing Medical Tourism Industry 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 2Health News:Donor-Assisted Conception Sparks Disclosure Dilemmas 3Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 2Health News:Real Salt Lake Teams Up with Nothing But Nets to Fight Malaria 3Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 2Health News:HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications 3
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
... Diagnosis & Treatment in Cardiology provides ... and manage patients with cardiac diseases. ... 200 cardiac diseases, each reviewed with ... pertinent information including: differential diagnosis, treatment, ...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
Medicine Products: